However, the impact of treatment with GLP-1 analogue on vascular dysfunction, LV function, NT-proBNP and oxidative stress burden have not been clearly defined in patients with T2DM and no CVD history. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.